Abstract:Cullin-RING E3 ligases (CRLs) are the major components of ubiquitin-proteasome system, responsible for ubiquitylation and subsequent degradation of thousands of cellular proteins. CRLs play vital roles in the regulation of multiple cellular processes, including cell cycle, cell apoptosis, DNA replication, signalling transduction among the others, and are frequently dysregulated in many human cancers. The discovery of specific neddylation inhibitors, represented by MLN4924, has validated CRLs as promising targets for anti-cancer therapies with a growing market. Recent studies have focused on the discovery of the CRLs inhibitors by a variety of approaches, including high through-put screen, virtual screen or structure-based drug design. The field is, however, still facing the major challenging, since CRLs are a large multi-unit protein family without typical active pockets to facilitate the drug design, and enzymatic activity is mainly dependent on undruggable protein-protein interactions and dynamic conformation changes. Up to now, most reported CRLs inhibitors are aiming at targeting the F-box family proteins (e.g., SKP2, β-TrCP and FBXW7), the substrate recognition subunit of SCF E3 ligases. Other studies reported few small molecule inhibitors targeting the UBE2M-DCN1 interaction, which specifically inhibits CRL3/CRL1 by blocking the cullin neddylation. On the other hand, several CRL activators have been reported, such as plant auxin and immunomodulatory imide drugs, thalidomide. Finally, proteolysis-targeting chimeras (PROTACs) has emerged as a new technology in the field of drug discovery, specifically targeting the undruggable protein-protein interaction. The technique connects the small molecule that selectively binds to a target protein to a CRL E3 via a chemical linker to trigger the degradation of target protein. The PROTAC has become a hotspot in the field of E3-ligase-based anti-cancer drug discovery.

Targeting kelch-like (KLHL) proteins: Achievements, challenges and perspectives

Kelch-like Proteins: Physiological Functions and Relationships with Diseases

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

The Functions and Properties of Cullin-5, a Potential Therapeutic Target for Cancers.

Update on the Kelch-like (KLHL) gene family

Targeting Cul3-scaffold E3 ligase complex <i>via</i> KLHL substrate adaptors for cancer therapy

Cullin-RING ligases in regulation of autophagy

KLHL20 and its role in cell homeostasis: A new perspective and therapeutic potential

Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases

Targeting Cullin-RING E3 ligases for anti-cancer therapy:efforts on drug discovery

Kelch-like Proteins in the Gastrointestinal Tumors

CRL3s: The BTB-CUL3-RING E3 Ubiquitin Ligases

Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8

A review: targeting UBR5 domains to mediate emerging roles and mechanisms - chance or necessity?

Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases

Cullin-RING Ligases as attractive anti-cancer targets.

Expression, Purification, and Microscopic Characterization of the Tumor Suppressor KLHL6

A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3

The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies

Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules

Exploring the target scope of KEAP1 E3 ligase-based PROTACs